Statements (17)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
Thomas K. Equels
|
| gptkbp:country |
gptkb:United_States
|
| gptkbp:focusesOn |
infectious diseases
oncology immunotherapy rare diseases |
| gptkbp:formerName |
Hemispherx Biopharma
|
| gptkbp:foundedYear |
1990
|
| gptkbp:headquartersLocation |
gptkb:Ocala,_Florida,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
AIM ImmunoTech
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:product |
Ampligen
|
| gptkbp:tradedOn |
NYSE American: AIM
|
| gptkbp:website |
https://aimimmuno.com/
|
| gptkbp:bfsParent |
gptkb:Phil_Mittleman
|
| gptkbp:bfsLayer |
7
|